Evaluating eribulin's ability to produce a cytokine immune response in lung cancer
Mines Repository · 05.12.2023
DOI: 10.25676/11124/178590 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mines Repository, erschienen am 05.12.2023. Verfasst von Wyatt Hinkle und 5 weiteren Autor:innen.
Abstract (Originalsprache)
This study aims to examine the ability of Eribulin, a non-taxane microtubule inhibitor, to induce a cytokine immune response similar to that of targeted TKI's in lung cancer cell lines, and furthermore to characterize the cytokine response to general growth arrest therapies compared to specific targeted protein kinase inhibitors such as TKI's.
Schlagwörter
Zitieren
APA
Hinkle, W., Hinz, K., T., Gurulé, J., N., & Heasley, L. E. (2023). Evaluating eribulin's ability to produce a cytokine immune response in lung cancer. Mines Repository. https://doi.org/10.25676/11124/178590
Vancouver
Hinkle W, Hinz, K. T, Gurulé, J. N, Heasley LE. Evaluating eribulin's ability to produce a cytokine immune response in lung cancer. Mines Repository. 2023. doi:10.25676/11124/178590
BibTeX
@article{Hinkle2023,
author = {Hinkle, Wyatt and Hinz and K., Trista and Gurulé and J., Natalia and Heasley, Lynn E.},
title = {Evaluating eribulin's ability to produce a cytokine immune response in lung cancer},
journal = {Mines Repository},
year = {2023},
doi = {10.25676/11124/178590}
}
EUVIMED